olivLaw · European equity research
Gentian Diagnostics Asa GENT.OL
Norway · Euronext Oslo Børs · ISIN NO0010748866 · Vertical: Listed companies from Norway
At the close of 04 Nov 2026, Gentian Diagnostics Asa (GENT.OL) stock was 39.90 NOK (+1.01% on the day), with market capitalisation 6.2 m NOK, P/E 0.5 on diluted EPS of 86.00 NOK over the last 12 months, dividend yield 100.31%, beta 0.24, 52-week range 34.60–59.00 NOK.
Data as of · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 55.2
- strong (55–70)
- Bollinger (20, 2)
- 37.76 – 40.57
- in the upper half of the band · %B 0.76 · band width 7.2%
- SMA 50 / 200
- 38.88 / 40.57
- mixed trend
- MACD (12, 26, 9)
- 0.22 / 0.19
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | +4.7% | −1.5% | +6.2 pp | — |
| 3 months | −2.2% | −5.3% | +3.1 pp | — |
| 6 months | +1.0% | +4.7% | −3.7 pp | — |
| Year to date | −29.3% | +6.0% | −35.3 pp | — |
| 1 year | −28.2% | +8.2% | −36.4 pp | −5.3% |
| 3 years | −0.3% | +47.2% | −47.4 pp | +15.4% |
| 5 years | −46.8% | +41.8% | −88.6 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 50 percentile of its own 2-quarter history (min 0.1, median 0.4, max 0.7; quarters with earnings only).
Fiscal years
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | unavailable | 135.2 m | 152.1 m | 176.5 m |
| Revenue YoY | unavailable | unavailable | +12.5% | +16.1% |
| Net income | 45.3 m | 45.3 m | 45.3 m | 13.3 m |
| Net income YoY | unavailable | 0.0% | 0.0% | −70.7% |
| Diluted EPS | unavailable | -0.69 | 287.00 | 86.00 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | −70.0% |
| net % | unavailable | 33.5% | 29.8% | 7.5% |
| Free cash flow | unavailable | 14.5 m | 12.1 m | 41.4 m |
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 105.9 m NOK
- Financial debt
- unavailable NOK
- Net debt
- unavailable NOK
- Equity
- 205.0 m NOK
- Total assets
- 258.5 m NOK
- Debt / equity
- unavailable
- Current ratio
- 5.40x
- ROE
- 6.6%
- ROA
- 5.4%
- FCF margin
- 23.4%
Financial statements (source on every figure)
Revenue and net income (NOK)
Margins
Income statement · NOK
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Revenue | — | 135.2 m | 152.1 m | 176.5 m | esef· 21 Oct 2026verified |
| Gross profit | — | 64.2 m | 82.8 m | 98.2 m | esef· 21 Oct 2026verified |
| Research & development | — | 36.1 m | 21.9 m | 23.2 m | esef· 21 Oct 2026verified |
| Operating income | — | -12.8 m | 15.7 m | 25.5 m | esef· 21 Oct 2026verified |
| Interest expense | — | 3.4 m | 2.5 m | 5.2 m | esef· 21 Oct 2026verified |
| Pre-tax income | — | -10.4 m | 20.1 m | 25.7 m | esef· 21 Oct 2026verified |
| Income tax | — | 282.0 k | -25.2 m | 12.4 m | esef· 21 Oct 2026verified |
| Net income | 45.3 m | 45.3 m | 45.3 m | 13.3 m | esef· 21 Oct 2026verified |
| Diluted EPS | — | -0.69 | 287.00 | 86.00 | esef· 21 Oct 2026verified |
| Dividend per share | — | — | 0.00 | 40.02 | esef· 21 Oct 2026derived |
Balance sheet · NOK
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Cash | 81.6 m | 87.6 m | 84.7 m | 105.9 m | esef· 21 Oct 2026verified |
| Receivables | — | 17.0 m | 31.3 m | 24.3 m | esef· 21 Oct 2026verified |
| Current assets | — | 141.7 m | 162.0 m | 184.3 m | esef· 21 Oct 2026verified |
| Property, plant & equipment, net | — | 7.8 m | 6.3 m | 4.4 m | esef· 21 Oct 2026verified |
| Intangibles (excl. goodwill) | — | 21.2 m | 28.5 m | 35.8 m | esef· 21 Oct 2026verified |
| Total assets | — | 181.0 m | 229.7 m | 258.5 m | esef· 21 Oct 2026verified |
| Current liabilities | — | 25.3 m | 30.1 m | 34.1 m | esef· 21 Oct 2026verified |
| Total liabilities | — | 34.4 m | 35.6 m | 53.6 m | esef· 21 Oct 2026verified |
| Equity | 154.2 m | 146.6 m | 194.1 m | 205.0 m | esef· 21 Oct 2026verified |
| Shares outstanding at year end | — | — | 154.1 k | 154.1 k | esef· 21 Oct 2026derived |
Cash flow · NOK
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Operating cash flow | — | 15.5 m | 13.5 m | 42.6 m | esef· 21 Oct 2026verified |
| Capex | — | 955.0 k | 1.4 m | 1.2 m | esef· 21 Oct 2026verified |
| Free cash flow | — | 14.5 m ≈ | 12.1 m ≈ | 41.4 m ≈ | esef· 21 Oct 2026derived |
| Investing cash flow | — | -4.9 m | -11.0 m | -10.8 m | esef· 21 Oct 2026verified |
| Financing cash flow | — | -4.6 m | -5.0 m | -11.1 m | esef· 21 Oct 2026verified |
| Dividends paid | — | — | 0 | 6.2 m | esef· 21 Oct 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 52.1% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 6.2 m NOK
Key indicators
Coverage and freshness
Score by group
52% · Insufficient data
Estimated value range
unavailable — no valuation assumptions for the reporting currency
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
Assumptions (illustrative, editorial)
- Risk-free rate
- 6.5%
- Equity risk premium
- 6.0%
- Beta (default)
- 1.00
- Cost of equity
- 12.5%
- Terminal growth
- 3.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 52.1% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 7.5% | 58 (vs peers) | 12% |
| FCF conversion · Quality | 312.2% | 100 (on a fixed band) | 12% |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 4.9x | 52 (on a fixed band) | 12% |
| Current ratio · Balance sheet | 5.4x | 100 (on a fixed band) | 8% |
| P/E (TTM) · Valuation | 0.5x | 95 (vs peers) | 20% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 672.9% | 100 (on a fixed band) | 16% |
| Shareholder yield (distributions) · Returns | 100.3% | 100 (on a fixed band) | 12% |
| Payout ratio (FCF) · Returns | 14.9% | 100 (on a fixed band) | 8% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet71/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality79/100 · 2/3 factors with a value
- Returns100/100 · 2/2 factors with a value
- Valuation97/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
GENTIAN DIAGNOSTICS ASA (GENT.OL). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 176.5 m NOK in 2025; YoY growth 16.1%; net margin 7.5%; ROE 6.6%.
The estimated value range is 600.46–1,603.07 NOK per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 1,073.50 NOK, the price of 39.90 NOK leaves a potential of 2,590.5% (value / price − 1) and a margin of safety of 96.3% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 52.1% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- FCF conversion: 312.2%
- Current ratio: 5.4x
- P/E (TTM): 0.5x
- FCF yield: 672.9%
- Shareholder yield (distributions): 100.3%
- Payout ratio (FCF): 14.9%
- The price is below the estimated value range
What contradicts it
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): ROIC, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, EV/EBITDA.
Versus the vertical median
Listed companies from Norway · same country · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AKER.OLAker Asa | 85.6 bn | 21.8 | 7.9% | 21.4% | +42.5% | +46% / +70% |
| AFG.OLAf Gruppen Asa | 21.6 bn | 19.9 | 39.7% | 3.4% | +4.4% | +9% / +71% |
| ELK.OLElkem Asa | 19.6 bn | 40.2 | 1.9% | 2.7% | −15.7% | +12% / +77% |
| ATEA.OLAtea Asa | 19.0 bn | 22.0 | 19.7% | 2.3% | +8.1% | +15% / +40% |
| AKSO.OLAker Solutions Asa | 17.6 bn | 6.9 | 22.5% | 4.1% | +19.2% | +19% / −11% |
| AUSS.OLAustevoll Seafood Asa | 16.7 bn | 37.2 | 1.6% | 1.1% | +11.1% | −6% / +11% |
| BRG.OLBorregaard Asa | 15.5 bn | 25.1 | 11.4% | 8.0% | +1.3% | −18% / −10% |
| BONHR.OLBonheur ASA | 11.2 bn | 7.9 | 17.1% | 11.4% | −10.8% | +18% / +45% |
| AFK.OLArendals Fossekompani Asa | 10.3 bn | — | -2.3% | -3.1% | −14.9% | +38% / +30% |
| B2I.OLB2 Impact Asa | 8.7 bn | 14.2 | 11.0% | 16.4% | +2.6% | +39% / +236% |
| AKVA.OLAkva Group Asa | 5.8 bn | 31.3 | 13.7% | 4.2% | +24.4% | +74% / +153% |
| BOUV.OLBouvet Asa | 5.1 bn | 14.5 | 80.7% | 9.2% | −0.2% | −18% / −14% |
| ELMRA.OLElmera Group Asa | 5.1 bn | 32.0 | 10.5% | 1.3% | −0.9% | +32% / +98% |
| CLOUD.OLCloudberry Clean Energy Asa | 3.9 bn | 61.2 | 1.3% | 13.1% | +34.0% | −6% / +28% |
| ABG.OLAbg Sundal Collier Holding Asa | 3.7 bn | 10.9 | 34.9% | 16.8% | +12.4% | −11% / +22% |
| ANDF.OLAndfjord Salmon Group As | 2.2 bn | — | -5.7% | -12,770.4% | +328.9% | −14% / −7% |
| BMA.OLByggma Asa | 1.6 bn | — | -25.3% | -11.9% | −2.5% | +61% / +15% |
| APR.OLAppear Asa | 1.4 bn | 10.9 | 30.1% | 16.1% | +32.3% | −51% / unavailable |
| AZT.OLArcticzymes Technologies Asa | 1.1 bn | 110.5 | 2.9% | 8.6% | +7.9% | −7% / −47% |
| CAPSL.OLCapsol Technologies Asa | 868.8 m | — | -89.4% | -114.8% | −25.0% | −34% / −67% |
| BOR.OLBorgestad Asa | 563.7 m | 36.8 | 2.1% | 1.4% | −3.0% | −5% / +44% |
| ARR.OLArribatec Group Asa | 239.5 m | 4.9 | 22.1% | 9.3% | +15.7% | −31% / −54% |
| DELIA.OLDellia Group Asa | 73.4 m | 1.5 | 22.6% | 7.7% | +140.0% | −62% / unavailable |
| ABTEC.OLAqua Bio Technology Asa | 11.9 m | 0.1 | — | 7,297.7% | −87.2% | −81% / −97% |
| GENT.OLGentian Diagnostics Asa | 6.2 m | 0.5 | 6.6% | 7.5% | +16.1% | −26% / +1% |
1- and 3-year price returns: for GENT.OL from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (NOK)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 26.07 Total return 53% · Per year 53% | 45.88 Total return 130% · Per year 130% | 68.83 Total return 211% · Per year 211% |
| 3 years | 30.93 Total return 264% · Per year 54% | 60.68 Total return 453% · Per year 77% | 99.11 Total return 652% · Per year 96% |
| 5 years | 36.68 Total return 514% · Per year 44% | 80.25 Total return 879% · Per year 58% | 142.72 Total return 1,288% · Per year 69% |
- Exit P/E± 15.17
- Net margin± 10.62
- Annual revenue growth± 7.92
- Annual dilution± 0.89
AI analysis
The qualitative analysis has not been written for this company yet.
Products, market & competition
The qualitative analysis has not been written for this company yet.
News & filings
In the press
No news in our archive over the last 180 days.
Annual reports (ESEF)
- Annual report 202521 Oct 2026
- Annual report 202408 May 2025
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.